comparemela.com

Latest Breaking News On - Kristenm stewart - Page 9 : comparemela.com

BD to Build New €165 Million Manufacturing Facility in Zaragoza, Spain To Support Ongoing Strong Growth of Pre-Filled Drug Delivery Business

BD to Build New €165 Million Manufacturing Facility in Zaragoza, Spain To Support Ongoing Strong Growth of Pre-Filled Drug Delivery Business
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

BD Announces Industry-First CE Marked Assay for HPV Screening from At-Home Self-Collected Vaginal Samples

Share this article Share this article FRANKLIN LAKES, N.J., May 13, 2021 /PRNewswire/ BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the industry s first self-collection claim for HPV screening has been CE marked to the IVD directive 98/79/EC. The new claim allows laboratories and facilities to process self-collected samples via a BD diluent tube using the BD Onclarity™ HPV Assay on either the BD Viper™ LT or the BD COR™ System. The BD Viper™ LT is in use globally and the BD COR™ System, launched last year, is in use across Europe. BD Onclarity™ HPV Assay 3-Well PCR Reagent Wells

Becton Dickinson & Co (BDX) Q2 2021 Earnings Call Transcript

Operator Hello, and welcome to BD s Second Fiscal Quarter 2021 Earnings Call. At the request of BD, today s call is being recorded. It will be available for replay through May 13, 2021 on the Investors page of the bd.com website or by phone at (855) 859-2056 for domestic calls and area code (404) 537-3406 for international calls using confirmation number 6334356. I would like to inform all parties that your lines have been placed in a listen-only mode until the question-and-answer segment. Beginning today s call is Ms. Kristen Stewart, Senior Vice President of Strategy and Investor Relations. Ms. Stewart, you may begin. Kristen M. Stewart

BD Announces Second Fiscal Quarter Results; Reaffirms Fiscal 2021 Guidance

BD Announces Second Fiscal Quarter Results; Reaffirms Fiscal 2021 Guidance - Second fiscal quarter revenues of $4.9 billion grew 15.4% on a reported basis. On a currency-neutral basis, revenues increased 12.2%. - BD s COVID-19 testing sales were $480 million, including BD Veritor™ Plus System revenues of $290 million. - BD s core growth led by strong growth in Medication Delivery Solutions (up 10.4%), Pharmaceutical Systems (up 15.4%), and Biosciences (up 16.3%) on a reported basis. - Second fiscal quarter GAAP diluted earnings per share (EPS) increased 77.4% year-over-year to $0.94. - Adjusted EPS increased 25.1% year-over-year to $3.19. - BD is reaffirming its fiscal 2021 revenue growth and adjusted EPS guidance. News provided by Share this article

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.